Interested in specific Information?

Filter what you see here

Patients eligible for transplant

Quick poll

Ixazomib all-oral triplet as consolidation treatment for newly diagnosed…

Ixazomib all-oral triplet as consolidation treatment for newly diagnosed multiple myeloma

Closes Dec 13, 2018

Patients eligible for transplant

Quick poll

Long-term follow-up of double vs single ASCT in patients with newly…

Closes Dec 13, 2018

General MM

Quick poll

Bruno Paiva | ASH 2018 | The clinical significance of MRD for high-risk…

Closes Dec 13, 2018

Relapsed/refractory patients

Quick poll

CAR T cell clinical trial for patients with relapsed/refractory multiple…

CAR T cell clinical trial for patients with relapsed/refractory multiple myeloma using bb21217

Closes Dec 11, 2018

General MM

Quick poll

Jonathan Keats | ASH 2018 | Development of genomic approaches to…

Closes Dec 11, 2018

Quick poll

Graham Jackson | ASH 2018 | Update on the efficacy and safety of the…

Closes Dec 6, 2018

General MM

Quick poll

Paola Neri | ASH 2018 | Enhancer deregulation in multiple myeloma

Paola Neri | ASH 2018 | Enhancer deregulation in multiple myeloma

Closes Dec 6, 2018

General MM

Quick poll

Nikhil Munshi | ASH 2018 | Biological significance of non-coding mutations…

Closes Dec 5, 2018

Patients eligible for transplant

Quick poll

ASH 2018 | Update on the Forte trial: a phase III clinical trial for newly…

Closes Dec 5, 2018

General MM

Quick poll

Shaji Kumar | ASH 2018 | ASH 2018: Some key highlights

Shaji Kumar | ASH 2018 | ASH 2018: Some key highlights

Closes Dec 4, 2018

General MM

Quick poll

Bruno Paiva | ASH 2018 | The clinical significance of MRD for high-risk…

Closes Dec 4, 2018

General MM

Quick poll

Lawrence Boise | ASH 2018 | The prognostic value of immunoglobulin lambda…

Closes Dec 4, 2018

General MM

Quick poll

Gareth J. Morgan | ASH 2018 | What are chromothripsis and chromoplexy and…

Gareth J. Morgan | ASH 2018 | What are chromothripsis and chromoplexy and how do they relate to MM?

Closes Dec 3, 2018

General MM

Quick poll

Elena Zamagni | ASH 2018 | New criteria for determining the role of PET/CT…

Closes Dec 3, 2018

General MM,   Relapsed/refractory patients

Quick poll

The gap between clinical trial and real-world practice outcomes in…

Closes Nov 22, 2018
A global online educational platform sharing the latest research and emerging treatment information in multiple myeloma

Latest Medical Information

Latest Congress Coverage

English & Spanish

Latest Biology

Latest Drug Updates

Relapsed/refractory patients

FDA approves elotuzumab in combination with pomalidomide and dexamethasone for…

Nov 8, 2018 , Expert Opinion

Recently updated Licenses

Where we are next

60th ASH Annual Meeting & Exposition

December 1–4, 2018 | San Diego, CA

The meeting prides itself on bringing together professionals worldwide to highlight 'state-of-the-art clinical practice and the latest findings in hematology research'. The program covers all hematological indications, including multiple myeloma. Stay tuned to follow our first-hand ASH coverage.

#ASH18 #mmsm 

Event Website

Map Data
Map data ©2018 Google
Map DataMap data ©2018 Google
Map data ©2018 Google

Connect with us

Our sister hubs

Visit our other community physician education hubs in haematology and oncology